PDF(Pubmed)
Abstract：
The utilization of chimeric antigen receptor (CAR) T-cell therapy to target cluster of differentiation (CD)19 in cancer immunotherapy has been a recent and significant advancement. Although this approach is highly specific and selective, it is not without complications. Therefore, a systematic review was conducted to assess the current state of positron emission tomography (PET) in evaluating the adverse effects induced by CAR T-cell therapy. A thorough search of relevant articles was performed in databases such as PubMed, Scopus, and Web of Science up until March 2024. Two reviewers independently selected articles and extracted data, which was then organized and categorized using Microsoft Excel. The risk of bias and methodological quality was assessed. In total, 18 articles were examined, involving a total of 753 patients, in this study. A wide range of utilities were analyzed, including predictive, correlative, and diagnostic utilities. While positive outcomes were observed in all the mentioned areas, quantitative analysis of the included studies was hindered by their heterogeneity and use of varying PET-derived parameters. This study offers a pioneering exploration of this promising field, with the goal of encouraging further and more focused research in upcoming clinical trials.
摘要：
在癌症免疫疗法中利用嵌合抗原受体（CAR）T细胞疗法靶向分化簇（CD）19是最近的重大进展。尽管这种方法具有很强的特异性和选择性，它并非没有并发症。因此,我们进行了系统评价,以评估正电子发射断层扫描(PET)在评估CAR-T细胞治疗引起的不良反应方面的现状.在PubMed等数据库中对相关文章进行了彻底的搜索，Scopus,和WebofScience直到2024年3月。两名审稿人独立选择文章并提取数据，然后使用MicrosoftExcel进行组织和分类。评估偏倚风险和方法学质量。总的来说,检查了18篇文章，共涉及753名患者，在这项研究中。分析了广泛的公用事业，包括预测性，相关的，和诊断实用程序。虽然在上述所有领域都取得了积极成果，纳入研究的异质性和使用不同的PET衍生参数阻碍了对纳入研究的定量分析.这项研究为这个有前途的领域提供了开创性的探索，目的是在即将进行的临床试验中鼓励进一步和更有针对性的研究。
